Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3929321 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNA4CHRM1SLC6A2HTR1A | |
| SCHEMBL2146138 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNA4CHRM1SLC6A2HTR1A | |
| Hydrochloric Acid SCHEMBL3197879 | 0.98 | CHRNB2 (0.33) | CHRNB2CHRNA4CHRM1SLC6A2HTR1A | |
| Oxalic Acid SCHEMBL21590791 | 0.88 | SLC6A1 (0.36) | — | |
| SCHEMBL7419570 | 0.86 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRM1SLC6A2HTR1A | |
| SCHEMBL76964 | 0.85 | HRH1 (0.35) | — | |
| Hydrochloric Acid SCHEMBL77415 | 0.83 | HRH1 (0.34) | — | |
| SCHEMBL22488269 | 0.82 | SLC6A2 (0.33) | CHRNB2CHRNA4CHRM1SLC6A2HTR1A | |
| SCHEMBL12436383 | 0.82 | CHRNB2 (0.32) | CHRNB2CHRNA4CHRM1SLC6A2HTR1A | |
| SCHEMBL22488272 | 0.82 | SLC6A2 (0.33) | CHRNB2CHRNA4CHRM1SLC6A2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239750-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20150045367-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | PHARMACYCLICS LLC | 2015-02-12 | — | — | US | disclosed |
| US-8841462-B2 | Bicyclic heterocycles as MEK kinase inhibitors | GENENTECH, INC. | 2014-09-23 | — | — | US | disclosed |
| US-8492427-B2 | Isoindolones derivatives as MEK kinase inhibitors and methods of use | GENENTECH, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8486963-B2 | Azaindolizines and methods of use | GENENTECH, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8293763-B2 | 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents | GENENTECH, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8288408-B2 | 5-anilinoimidazopyridines and methods of use | GENENTECH, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8258152-B2 | N-substituted azaindoles and methods of use | GENENTECH, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258152-B2 | N-substituted azaindoles and methods of use | GENENTECH, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110190257-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | GENETECH, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20100216768-A1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | GENENTECH, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216768-A1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | GENENTECH, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | GENENTECH, INC. | 2008-04-03 | — | — | US | disclosed |
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | GENENTECH, INC. | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190257-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | MAP2K7, MAP3K1, MAP3K5 | CHRNB2 4817/4885CHRNA4 4866/4885CHRM1 4821/4885 |
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | MKI67, CDKN1A, MAP3K1 | CHRNB2 4799/4885CHRNA4 4817/4885CHRM1 4599/4885 |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | CDKN1A, MKI67, CCNI | CHRNB2 4188/4885CHRNA4 3986/4885CHRM1 3301/4885 |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | MAP3K2, MAP3K1, MAP2K2 | CHRNB2 4746/4885CHRNA4 4874/4885CHRM1 4599/4885 |
| US-20100216768-A1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | MKI67, CCNI, CDKN1A | CHRNB2 4337/4885CHRNA4 4518/4885CHRM1 4047/4885 |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | MKI67, MAP3K5, MAPKAPK5 | CHRNB2 4515/4885CHRNA4 4072/4885CHRM1 4023/4885 |
| US-20150045367-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | HDAC8, HDAC5, HDAC7 | CHRNB2 4249/4885CHRNA4 4350/4885CHRM1 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.